N. Danny Shulman

Specialist in venture financing and capital markets with a life‑sciences focus — Shulman's practice centers on representing emerging and public biotechnology and medical device companies, advising on venture financings, IPOs, follow-on offerings, ATMs, PIPEs and other securities transactions. honigman+1

Proven capital‑markets deal experience from an AmLaw firm background — he spent nearly a decade at a global AmLaw firm managing cross‑functional teams on more than 100 complex capital markets matters for issuers and underwriters. honigman+1

Active on securities matters for public companies — he has been listed as counsel or contact on multiple SEC and corporate filings and has worked on IPOs, follow-on offerings and other registry and underwriting transactions. bioxceltherapeutics+2

Strong academic background in law and business — earned a J.D. with honors from Penn Law, served as a senior editor of the Penn Law Review, and completed a Wharton certificate while holding dual undergraduate degrees with high academic distinction. upenn+2